-transparent.png){kind=logo}
Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or beta-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study. Significant reduction in mean blood pressure was achieved. Supine and erect systolic and diastolic blood pressure fell by 44/25 mmHg and 37/24 mmHg respectively over the study period of 12 weeks. Side-effects such as dizziness, headache, facial flushing and mild oedema were experienced by 10 patients during the study, all of which were mild and transient and did not require withdrawal from pinacidil therapy. Pinacidil is an effective and well tolerated agent in the treatment of essential hypertension.
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1984,
European journal of clinical pharmacology,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1985,
European journal of clinical pharmacology,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1983,
European journal of clinical pharmacology,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
October 1991,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1988,
Drugs,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
October 1989,
Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1990,
Clinical therapeutics,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1991,
Clinical therapeutics,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1992,
Clinical therapeutics,
V D'Arcy, and
M Laher, and
D McCoy, and
P Sullivan, and
C H Walsh, and
M P Hickey
January 1985,
Advances in prostaglandin, thromboxane, and leukotriene research,
